Stockscreener 앱 받기
301.25
1.01%
1.80
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
Krystal Biotech (KRYS) Investor Outlook: Robust Growth Prospects with 8.32% Potential Upside - DirectorsTalk Interviews
Precision Trading with Krystal Biotech Inc. (KRYS) Risk Zones - Stock Traders Daily
Krystal Biotech Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $364 - Moomoo
KRYS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $310 - GuruFocus
KRYS Technical Analysis | Trend, Signals & Chart Patterns | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill
Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end - MSN
Krystal Biotech, Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart
Krystal Biotech Shareholders Approve Directors and Compensation - TipRanks
The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability - Sahm
Krystal Biotech Inc stock (US5012681064): HC Wainwright confirms Buy as UK clears VYJUVEK - AD HOC NEWS
Krystal Biotech gains regulatory approval to sell gene therapy in the United Kingdom - The Business Journals
Krystal Biotech Q1 earnings & sales beat estimates, pipeline in focus - MSN
Krystal Biotech receives UK approval for gene therapy VYJUVEK By Investing.com - Investing.com South Africa
Krystal Biotech receives UK approval for gene therapy VYJUVEK - Investing.com
Krystal Biotech's (KRYS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times
First UK genetic medicine for DEB lets some patients treat wounds at home - Stock Titan
Krystal Biotech Price Target Maintained With a $310.00/Share by HC Wainwright & Co. - Moomoo
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings and Promising 5.38% Upside Potential - DirectorsTalk Interviews
Krystal Biotech Inc stock (US5012681064): gene therapy player draws attention after shareholder meet - AD HOC NEWS
VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stock Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Assessing Krystal Biotech (KRYS) Valuation After First Quarter Earnings and EPS Growth - Sahm
Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Krystal Biotech (KRYS) Receives Approval for Innovative Wound Tr - GuruFocus
KRYS: All proposals, including director elections and compensation policies, were approved - TradingView
Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK - Moomoo
Krystal Biotech Inc Annual Shareholders Meeting Transcript - GuruFocus
Krystal Biotech Inc Phase 1/2 Clinical Trial of KB103 Final Update Call Transcript - GuruFocus
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating - Moomoo
Why is Krystal Biotech (KRYS) down 11.5% since last earnings report? - MSN
Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $330.56, Implies 6% Upside - TradingView
Krystal Biotech stock (US5012681064): Hits all-time high near $316 - AD HOC NEWS
Technical Reactions to KRYS Trends in Macro Strategies - Stock Traders Daily
Krystal Biotech stock hits all-time high at 315.68 USD By Investing.com - Investing.com India
There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings - simplywall.st
Krystal Biotech stock hits all-time high at 315.68 USD - Investing.com
This Profitable Biotech Stealthily Climbs Into A Buy Zone - Investor's Business Daily
Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week HighHere's Why - MarketBeat
Krystal Biotech's (NASDAQ:KRYS) Earnings Are Of Questionable Quality - Moomoo
Krystal Biotech (KRYS) Is Up 6.5% After Vyjuvek-Fueled Q1 Profit Jump And Investor Conference Update - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings Signal Promising Upside - DirectorsTalk Interviews
State of New Jersey Common Pension Fund D Reduces Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Krystal Biotech (KRYS) Is Up 13.1% After Strong Q1 Earnings And FDA Nod For At-Home Vyjuvek Use – Has The Bull Case Changed? - simplywall.st
Krystal Biotech: Vyjuvek Is Not The Primary Asset (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech, Inc. $KRYS Shares Purchased by Principal Financial Group Inc. - MarketBeat
A Look At Krystal Biotech (KRYS) Valuation After Vyjuvek Powered Q1 2026 Earnings Beat - simplywall.st
KRYS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum - ChartMill
Krystal Biotech Inc (KRYS) Stock Price, Quote, News & History - Benzinga
Is It Too Late To Consider Krystal Biotech (KRYS) After Its Strong Share Price Run? - simplywall.st
2.25%
0.46%
자본화:
|
볼륨(24시간):